Tiziana Life Sciences announces dosing of new patients at Yale MS Center

Tiziana Life Sciences (TLSA) announced dosing of new patients at Yale MS Center which is participating in our multicenter Phase 2 clinical trial evaluating intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis, na-SPMS. Other centers are currently enrolling include Johns Hopkins, U Mass Medical Center and Brigham and Women’s Hospital. This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially mitigate the progression of SPMS. This multicenter study is important because it combines brain PET imaging, immunology, and measures of clinical evidence accepted by FDA.